Affana Parveen Mohamed

Affana Parveen Mohamed

Auto-generated profile, based on publicly available information

Affana Parveen Mohamed

College of Pharmacy

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 March 2022 in International Journal of Alzheimer's Disease
Verified
Journal Article
Open access
PDF file
SBSemira Beshir
Semira Beshir
AMAadith soorya Arunkumar Maivizhichelvi
Aadith soorya Arunkumar Maivizhichelvi
APAffana Parveen
Affana Parveen
SGSheron Goh
Sheron Goh
NHNadia Hussain
Nadia Hussain
VMVineetha Bharathan Menon
Vineetha Bharathan Menon
Background. Aducanumab, a new monoclonal antibody that targets β-amyloid aggregates, has been granted conditional approval by the U.S. FDA for treatment of mild Alzheimers disease (AD). The approval of this drug without a confirmed significant clinical impact has resulted in several debates. Objective. In this narrative review, aducanumab approval-related controversy, the drugs pharmacokinetics and pharmacodynamic characteristics, evidence from the efficacy and safety trials of aducanumab, implications of the drug approval, and the future directions in the management of patients with AD are summarized. Methods. Using relevant keywords, Google Scholar, Web of Science, and MEDLINE databases and manufacturers website were searched. Results. Infusion of aducanumab at a higher dose resulted in a modest slowing of cognitive decline among patients with mild cognitive impairment or early-onset AD dementia. The drug however can cause amyloid-related imaging abnormalities. Due to modest impact on cognition, the use of this drug by patients with AD will most likely be limited. The manufacturer is required to run an extended phase IIIb trial to verify the benefit of this drug. Access to therapy requires a careful selection of patients and periodic monitoring to ensure the optimal use of the drug. Conclusion. Despite the limitations, aducanumab is the first disease-modifying therapy approved for the treatment of AD. Aducanumab addresses a part of the pathogenesis of AD; therefore, drugs that can act on multiple targets are needed. In addition, the search for preventive strategies, validated plasma-based assays, and newer drugs for AD, which are effective, safe, convenient, and affordable, is vital.

1 January 2022 in Pharmacy Education
Verified
Journal Article
Open access
PDF file
SBSemira Beshir
Semira Beshir
AMAffana Parveen Mohamed
Affana Parveen Mohamed
AMAadith soorya Arunkumar Maivizhichelvi
Aadith soorya Arunkumar Maivizhichelvi
SGSheron Sir Loon Goh
Sheron Sir Loon Goh
EEEman Moussa El-Labadd
Eman Moussa El-Labadd
ASAmira S.A. Said
Amira S.A. Said
Background: This review summarises the impact of virtual patient simulation (VPS) on pharmacy students’ knowledge, skills, and perceptions. Methods: The PubMed, Cochrane Library, and Web of Science databases were searched using relevant keywords. Full-text articles in English, published between 2010 and August 2021, were retrieved if they evaluate the impact of web-based interactive VPS in pharmacy education. Results: This review included 19 studies, 9 of which were comparative. VPS was used to develop or assess different pharmacy-related skills. In general, post-VPS exposure test scores were better than the pre-VPS test scores in 12 studies. VPS significantly improved higher-level learning, counselling, and decision-making skills more than paper-based cases. The favourable impact of VPS on learners’ confidence, student engagement, and satisfaction was noted. Conclusion: VPS enhances knowledge and clinical decision-making skills. It can also address the needs of pharmacy students with active learning preferences.